Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has announced that the US Patent and Trademark Office has issued new patent which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.
Subscribe to our email newsletter
The new patent’s allowed claims include methods of treating a broad spectrum of viral infections, including HIV, influenza, hepatitis C virus and cytomegalovirus, using one or more anti-phospholipid antibodies that directly bind to an aminophospholipid target, either alone or in combination with other anti-viral agents.
The patent also covers anti-viral immunoconjugate compositions, methods and other combinations of anti-phospholipid antibodies and anti-viral agents.
Steven King, president and CEO of Peregrine, said: “Issuance of this broad anti-viral patent significantly expands our intellectual property leadership in the field of phospholipid-targeting antibodies.
‘Antibodies falling under the scope of this new patent are already showing promise in preclinical studies of lethal virus diseases including hemorrhagic fever and AIDS.”